GAITHERSBURG, Md., Dec. 13, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it has submitted a regulatory filing to the Ministry of Health and Prevention (MoHaP) for emergency use of its COVID-19 vaccine in the United Arab Emirates (UAE).
"The rapid emergence and continuedspread of variants is a stark reminder that no one is safe until everyone is safe in the fight against COVID-19," said Stanley C. Erck, President and Chief Executive Officer, Novavax. "We remain committed to delivering our vaccine, which is based on a proven, well understood platform, to countries around the world as we anticipate that ongoing vaccination will be necessary over the long term to end the pandemic."
Novavax made the submission for the regulatory evaluation by MoHaP of NVX-CoV2373, the company's recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M adjuvant. The filing includes clinical data from two pivotal Phase 3 clinical trials: PREVENT-19, which included 30,000 participants in the U.S. and Mexico and demonstrated 100% protection against moderate and severe disease, 93.2% efficacy against the predominantly circulatingvariants of concern and variants of interest, and 90.4% efficacy overall; and a trial of 15,000 participants in the U.K. that demonstrated efficacy of 96.4% against the original virus strain, 86.3% against the Alpha (B.1.1.7) variant and 89.7% efficacy overall. In both trials, NVX-CoV2373 demonstrated a reassuring safety and tolerability profile.
Novavax and Serum Institute of India Pvt. Ltd. (SII) recently received Emergency Use Authorization (EUA) for the vaccine inIndonesiaand thePhilippines, and the companies have filed for EUA inIndiaand for Emergency Use Listing (EUL) with theWorld Health Organization(WHO). Novavax also announced regulatory filings for its vaccine in theUnited Kingdom,Australia,New Zealand,Canada, theEuropean Union, Singapore and with theWHO.Additionally, Novavax and SK bioscience announced a Biologics License Application (BLA)submission to MFDSinSouth Korea. Novavax expects to submit the complete package to the U.S. FDA by the end of the year.
The chemistry, manufacturing and controls (CMC) data package submitted to MoHaP and other global regulatory agencies leverages Novavax' manufacturing partnership with SII, the world's largest vaccine manufacturer by volume. It will later be supplemented with data from additional manufacturing sites in Novavax' global supply chain.
About the NVX-CoV2373 Phase 3 trials
NVX-CoV2373 is being evaluated in two pivotal Phase 3 trials: a trial in the U.K. that demonstrated efficacy of 96.4% against the original virus strain, 86.3% against the Alpha (B.1.1.7) variant and 89.7% efficacy overall; and the PREVENT-19 trial in the U.S. and Mexico that demonstrated 100% protection against moderate and severe disease, 93.2% efficacy against the predominantly circulatingvariants of concern and variants of interest, and 90.4% efficacy overall. It was generally well-tolerated and elicited a robust antibody response.
About NVX-CoV2373
NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using Novavax' recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is formulated with Novavax' patented saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19.
Novavax' COVID-19 vaccine is packaged as a ready-to-use liquid formulation in a vial containing ten doses. The vaccination regimen calls for two 0.5 ml doses (5 mcg antigen and 50 mcg Matrix-M adjuvant) given intramuscularly 21 days apart. The vaccine is stored at 2- 8 Celsius, enabling the use of existing vaccine supply and cold chain channels.
About Matrix-M Adjuvant
Novavax' patented saponin-based Matrix-M adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. NVX-CoV2373, the company's COVID-19 vaccine, received Emergency Use Authorization in Indonesia and the Philippines and has been submitted for regulatory authorization in multiple markets globally. NanoFlu, the company's quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Novavax is currently evaluating a COVID-NanoFlu combination vaccine in a Phase 1/2 clinical trial, which combines the company's NVX-CoV2373 and NanoFlu vaccine candidates. These vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
For more information, visitwww.novavax.comand connect with us on Twitter,LinkedIn, Instagram and Facebook.
Forward-Looking Statements
Statements herein relating to the future of Novavax, its operating plans and prospects, its partnerships, the ongoing development of NVX-CoV2373, the scope, timing and outcome of future regulatory filings and actions, Novavax' plans to submit a complete package to the U.S. FDA by the end of the year, and Novavax' plan to supplement the CMC data submitted to the MoHaP with data from the additional manufacturing sites in Novavax' global supply chain are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy applicable regulatory authorities; difficulty obtaining scarce raw materials and supplies; resource constraints, including human capital and manufacturing capacity, on the ability of Novavax to pursue planned regulatory pathways; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities; and those other risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Novavax' Annual Report on Form 10-K for the year ended December 31, 2020 and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at http://www.sec.gov and http://www.novavax.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
Contacts:
Investors
Novavax, Inc.
Erika Schultz| 240-268-2022
Solebury Trout
Alexandra Roy| 617-221-9197
Media
Alison Chartan| 240-720-7804
Laura KeenanLindsey | 202-709-7521
Logo - https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg
Go here to see the original:
Novavax Files for Emergency Use of COVID-19 Vaccine in the United Arab Emirates - KPVI News 6
- Who are We? - November 7th, 2009 [November 7th, 2009]
- Vilsack targeted for his Pro-GMOs stand - November 7th, 2009 [November 7th, 2009]
- Call for technology to produce cellulosic ethanol - November 7th, 2009 [November 7th, 2009]
- Kenyan scientists weigh on GMOs - November 7th, 2009 [November 7th, 2009]
- Indian researcher makes a case for biotechnology - November 7th, 2009 [November 7th, 2009]
- Michigan smoothens the way for alternative energy investors - November 7th, 2009 [November 7th, 2009]
- Link of ethanol use to high food prices questioned - November 7th, 2009 [November 7th, 2009]
- EU challenges France on GM Maize - November 7th, 2009 [November 7th, 2009]
- POET rolls out cellulosic ethanol plant - November 7th, 2009 [November 7th, 2009]
- There’s a bright future for cellulosic ethanol investment - November 7th, 2009 [November 7th, 2009]
- Cellulosic ethanol can considerably reduce gasoline use by 2030 - November 7th, 2009 [November 7th, 2009]
- Human Genetic Engineering - Background - November 7th, 2009 [November 7th, 2009]
- Human Genetic Engineering - History - November 7th, 2009 [November 7th, 2009]
- Human Genetic Engineering - Methods - November 7th, 2009 [November 7th, 2009]
- Human Genetic Engineering - Uses - November 7th, 2009 [November 7th, 2009]
- Human Genetic Engineering - Controversy - November 7th, 2009 [November 7th, 2009]
- Human Genetic Engineering - In popular culture - November 7th, 2009 [November 7th, 2009]
- Human genetic engineering - An Introduction - November 7th, 2009 [November 7th, 2009]
- Human Genetic Engineering - A Very Hot Issue! - November 7th, 2009 [November 7th, 2009]
- What are the risks of genetic engineering in humans? (human genetic engineering) - November 7th, 2009 [November 7th, 2009]
- What are the benefits of human genetic engineering? (human genetic engineering) - November 7th, 2009 [November 7th, 2009]
- Genetic Engineering - Ethics and Controversy - November 7th, 2009 [November 7th, 2009]
- Genetic Engineering Ethics In Science Fiction - November 7th, 2009 [November 7th, 2009]
- Genetic Engineering Ethics - November 7th, 2009 [November 7th, 2009]
- Welcome to Pest Control Exterminator Network - December 13th, 2009 [December 13th, 2009]
- OMD - Genetic Engineering - August 27th, 2011 [August 27th, 2011]
- X-Ray Spex - Genetic Engineering - August 27th, 2011 [August 27th, 2011]
- Ancient Alien Nephilim, Giants, Mutants, Genetic Engineering, and Hybrids (2-6) - August 28th, 2011 [August 28th, 2011]
- Human-Plant Hybrid (Genetic Engineering at Home) - August 28th, 2011 [August 28th, 2011]
- Ancient Alien Nephilim, Giants, Mutants, Genetic Engineering, and Hybrids (1-6) - August 29th, 2011 [August 29th, 2011]
- 3. Genetic Engineering - August 29th, 2011 [August 29th, 2011]
- Genetic engineering nightmare - August 31st, 2011 [August 31st, 2011]
- Ancient Alien Nephilim, Giants, Mutants, Genetic Engineering, and Hybrids (3-6) - August 31st, 2011 [August 31st, 2011]
- Future of genetic engineering - by Futurist Dr Patrick Dixon. Genetic mutations and genetic disorders. Gene science by conference keynote speaker - September 2nd, 2011 [September 2nd, 2011]
- Genetic engineering: The world's greatest scam? - September 3rd, 2011 [September 3rd, 2011]
- Watch Fed Up! Genetic Engineering, Industrial Agriculture and Sustainable Alternatives Full Movie Online Part 1/15 - September 3rd, 2011 [September 3rd, 2011]
- Ancient Alien Nephilim, Giants, Mutants, Genetic Engineering, and Hybrids (5-6) - September 5th, 2011 [September 5th, 2011]
- Genetic Engineering, Humans with Animals. - September 6th, 2011 [September 6th, 2011]
- Is Genetic Engineering Good for the Environment? - September 7th, 2011 [September 7th, 2011]
- Open Source Food and Genetic Engineering - Michael Pollan - September 10th, 2011 [September 10th, 2011]
- Ancient Alien ( demons ) Nephilim Giants, Mutants Genetic Engineering and Hybrids.avi - September 11th, 2011 [September 11th, 2011]
- MUST SEE : Genetic Engineering Corn Grows in Sand ! For Those That Appreciate Nature ! - September 12th, 2011 [September 12th, 2011]
- Designing Humanity - Genetic Engineering - September 14th, 2011 [September 14th, 2011]
- Genetic Modification | QUEEN ANNE SCIENCE CAFE - September 14th, 2011 [September 14th, 2011]
- Genetic Engineering in California Agriculture - September 15th, 2011 [September 15th, 2011]
- Genetic Engineering Animation - September 15th, 2011 [September 15th, 2011]
- Proof Of Ancient Genetic Engineering - September 15th, 2011 [September 15th, 2011]
- Joad Cressbeckler Fears Genetic Modification Causes 'Wrath-Minded Taters' - September 16th, 2011 [September 16th, 2011]
- Ethical Concerns With Genetic Engineering - September 16th, 2011 [September 16th, 2011]
- Scientists under Attack - Genetic Engineering in the magnetic Field of Money TRAILER - September 17th, 2011 [September 17th, 2011]
- Genetic Modification - September 18th, 2011 [September 18th, 2011]
- Genetic Engineering Not a New Science - Pamela Ronald - September 23rd, 2011 [September 23rd, 2011]
- The Island of Dr. Moreau prt. IV - September 28th, 2011 [September 28th, 2011]
- Ancient Alien Nephilim, Giants, Mutants, Genetic Engineering, and Hybrids (4-6) - September 30th, 2011 [September 30th, 2011]
- 4. Genetic Engineering (cont.) - October 2nd, 2011 [October 2nd, 2011]
- Ancient Alien Nephilim, Giants, Mutants, Genetic Engineering, and Hybrids (6-6) - October 4th, 2011 [October 4th, 2011]
- Islands at Risk (Part 3) - Genetic Engineering in Hawai'i - October 4th, 2011 [October 4th, 2011]
- Morgellons Is Genetic Engineering , A Silent Superbug - October 4th, 2011 [October 4th, 2011]
- Islands at Risk (Part 2) - Genetic Engineering in Hawai'i - October 4th, 2011 [October 4th, 2011]
- The Ethics of Genetically Engineering Children - Arthur Caplan - October 4th, 2011 [October 4th, 2011]
- Disney Geneticists Debut New Child Stars - October 4th, 2011 [October 4th, 2011]
- Genetic Engineering and Society, Lecture 1a, Honors Collegium 70A, UCLA - October 4th, 2011 [October 4th, 2011]
- OMD - Genetic Engineering (312mm Version) (Audio Only) - October 4th, 2011 [October 4th, 2011]
- The difference between normal and genetically modified food - October 4th, 2011 [October 4th, 2011]
- Bioethics Of Human Genetic Engineering - Documentary Video - October 6th, 2011 [October 6th, 2011]
- Islands at Risk (Part 1) - Genetic Engineering in Hawai'i - October 6th, 2011 [October 6th, 2011]
- Coast To Coast AM: Genetic Engineering 3-24-2011 Download Link - October 6th, 2011 [October 6th, 2011]
- Lloyd Pye - Ancient Genetic Engineering - October 13th, 2011 [October 13th, 2011]
- X RAY SPEX - ROUNDHOUSE LONDON GENETIC ENGINEERING - Video - October 13th, 2011 [October 13th, 2011]
- OMD - Genetic Engineering 1983 - Video - October 14th, 2011 [October 14th, 2011]
- OMD - GENETIC ENGINEERING - Video - October 14th, 2011 [October 14th, 2011]
- Mechanism of Recombination - Video - October 15th, 2011 [October 15th, 2011]
- Harvard Prof. Michael Sandel on Human Genetic Modification, Berkeley, CA, 7 May 2007 - Video - October 15th, 2011 [October 15th, 2011]
- Genetic Engineering [Medical Ethics Series] - (excerpt) - Video - October 15th, 2011 [October 15th, 2011]
- Genetic Engineering and Society, Lecture 1b, Honors Collegium 70A, UCLA - Video - October 24th, 2011 [October 24th, 2011]
- Genomics: genetic modification (genetic engineering) and the human gene project - Video - October 26th, 2011 [October 26th, 2011]
- Genetically Engineering Intelligent Babies - Horizon: Are We Still Evolving? Preview - BBC Two - Video - October 27th, 2011 [October 27th, 2011]
- "GENETIC ENGINEERING" GERMAN REGIME feat THIRSTIN HOWL THE3RD - Video - October 28th, 2011 [October 28th, 2011]
- Science 360: Genetic Engineering - Video - October 31st, 2011 [October 31st, 2011]
- UFOTV Presents... - Bad Seed: Danger of Genetically Modified Food - Video - November 8th, 2011 [November 8th, 2011]